ClinicalTrials.gg
RecruitingNCT07368998optINAVOUpdated Nov 3, 2026

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

A Phase 2 interventional study of Inavolisib and Fulvestrant in Breast Cancer, sponsored by Hoffmann-La Roche. Recruiting at 34 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing inavolisib in Breast Neoplasms — 12 open to participants now, 15 under way, 4 of them phase 3. inavolisib · Breast Neoplasms.

Planned enrollment
13th of 16
80 · median 185
Started
2026
with 3 others
Phase 2
10 of 16
8 open now
Primary completion
2028-10
later than 8 of 14 live
Registered
13th of 16
by date
Lead sponsor
9 of 16
Hoffmann-La Roche

Among the 16 studies testing inavolisib in Breast Neoplasms, this one is the 13th largest by planned enrollment, is one of 4 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 8 of the 14 other live ones, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 16 studies testing inavolisib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About inavolisib

inavolisib: first FDA approval 2024 (ITOVEBI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inavolisib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented ER +/ - tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
  • Disease progression after or during treatment with a combination of CDK4/6i and endocrine therapy: \<= 1 in the locally advanced (recurrent or progressed) or setting
  • Measurable or evaluable disease per version 1.1 (RECIST v1.1)
  • Participants for whom endocrine-based therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines
  • Confirmation of biomarker eligibility: presence of >= 1 study-eligible PIK3CA mutation
  • of > 6 months
  • Ability, in the investigator's judgment, and willingness to comply with all study -related procedures, including completion of patient-reported outcomes

Exclusion criteria

Exclusion Criteria:

  • Metaplastic breast cancer
  • Prior treatment with chemotherapy in the recurrent locally advanced/ setting
  • Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
  • Prior treatment with PI3K/Akt/mTOR inhibitors in the recurrent locally advanced/metastatic setting
  • Requirement for daily supplemental oxygen
  • Symptomatic active lung disease, including pneumonitis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Inavolisib Dose A plus Fulvestrant

    Participants will recieve an inavolisib tablet orally (PO) along with fulvestrant as an intramuscular (IM) injection.

    Drug: Inavolisib · Drug: Fulvestrant

  • Experimental
    Inavolisib Dose B plus Fulvestrant

    Participants will recieve an inavolisib tablet PO along with fulvestrant as an IM injection.

    Drug: Inavolisib · Drug: Fulvestrant

Interventions

  • Participants will receive Inavolisib as per the schedule given in the protocol.

  • Participants will receive Fulvestrant as per the schedule given in the protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response Rate (ORR)

    Time frame: Up to approximately 2 years

  2. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Duration of Response (DOR)

    Time frame: Up to approximately 2 years

  2. Time to Response (TTR)

    Time frame: Up to approximately 2 years

  3. Progression-free Survival (PFS)

    Time frame: Up to approximately 2 years

  4. Percentage of Participants With Treatment Discontinuation due to Adverse Events

    Time frame: Up to approximately 2 years

  5. Number of Participants Reporting Presence, Frequency, Severity and/or Degree of Interference With Daily Activities of Symptomatic Treatment Toxicities as Assessed by NCI Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Time frame: Up to approximately 2 years

  6. Percentage of Participants Reporting Presence and Frequency of Selected Hyperglycemia Symptoms as Assessed by European Organisation for Research and Treatment of Cancer (EORTC) IL382

    Time frame: Up to approximately 2 years

  7. Percentage of Participants Reporting Each Response Option at Each Time Point for the Treatment Side-Effect Bother Item General Population, Question 5 (GP5) From the Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire

    Time frame: Up to approximately 2 years

  8. Change from Baseline in Symptomatic Treatment-Related Toxicities as Assessed Through use of the PRO-CTCAE

    Time frame: Baseline, Up to approximately 2 years

  9. Change from Baseline in Selected Hyperglycemia Symptoms as Assessed by EORTC IL382

    Time frame: Baseline, Up to approximately 2 years

  10. Change from Baseline in Treatment Side-effect Bother as Assessed Through use of the FACT-G GP5 Item

    Time frame: Baseline, Up to approximately 2 years

07

Study locations

34 of 34 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2028, 32 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 32 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2026
First posted
Jan 27, 2026
StartActual
Feb 18, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Oct 31, 2031
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07368998
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 27, 2026
Start date
Feb 18, 2026
Primary completion
Oct 31, 2028 (estimated)
Completion
Oct 31, 2031 (estimated)
Last update
Nov 3, 2026

Study contacts

Reference Study ID Number: WO46063 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inavolisib

Start the discussion